Loading
CheckMate 143 was the first large randomised test of an immune checkpoint drug in glioblastoma. When the tumour came back, nivolumab kept patients alive no longer than bevacizumab.
CheckMate 143, trial NCT02017717 sponsored by BMS, randomised 369 patients with glioblastoma at first recurrence after radiotherapy and temozolomide, open-label, to nivolumab 3 mg/kg or bevacizumab 10 mg/kg every two weeks. Median overall survival, the primary endpoint, was 9.8 versus 10.0 months (HR 1.04, 95% CI 0.83-1.30), 12-month survival was 42% in both arms, and the objective response rate was higher with bevacizumab (23.1% versus 7.8%). Published by Reardon and colleagues in JAMA Oncology in 2020. It is one of three negative phase 3 trials of nivolumab in glioblastoma, with CheckMate 498 and CheckMate 548 in newly diagnosed disease.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
369 enrolled.
Not significant
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survival, first recurrence of glioblastomaprimary | Nivolumab | 184 | 9.8 months | 1.04 (0.83 to 1.3) | 0.76 | link |
| Bevacizumab | 185 | 10 months |
Shares Neoadjuvant immunotherapy with surgical window for glioblastoma, Blood-brain barrier (BBB), Hot vs cold tumours, Nivolumab.
Shares Neoadjuvant immunotherapy with surgical window for glioblastoma, Blood-brain barrier (BBB), Hot vs cold tumours, Nivolumab.
Shares Hot vs cold tumours, Nivolumab, PD-1, Immune checkpoint inhibitors.
Shares Hot vs cold tumours, PD-1, Immune checkpoint inhibitors.
Shares Hot vs cold tumours, PD-1, Immune checkpoint inhibitors.
Shares Hot vs cold tumours, Glioma & glioblastoma, Immune checkpoint inhibitors.